Skip to main content
. 2011 Feb 1;27(1):7–13. doi: 10.1007/s12288-010-0048-9

Table 3.

Important results obtained during study

Patients with CHR (%) 78.04
Time to achieve CHR (weeks) 10.9
Patients with CCR (%) 12.2
Patients with MCR (%) 64.63
Patients with minor CR (%) 18.29
Patients with NCR (%) 4.88
Patients with cytopenias (any duration) requiring dose reduction (%) 43.9
Patients with cytopenias (>4 weeks) requiring dose reduction (%) 20.73
Mean TLC in patients with CCR (cells/mm3) 27,034
Mean TLC in patients with MCR (cells/mm3) 39,828
Mean TLC in patients with minor CR (cells/mm3) 66,764
Mean TLC in patients with NCR (cells/mm3) 72,102
Primary resistance to Imatinib (%) 4.88